Physician profile
Jason D Ackerman
NPI 1396060604
$1,198.42
in general payments reported to CMS, 2019-2025
23 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Addiction Medicine (Internal Medicine) provider received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $166 · 2021: $172 · 2022: $171 · 2023: $207 · 2024: $191 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.23 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $209.69 | 2021-2024 | Vraylar, Mavyret |
| Alkermes, INC. | $96.85 | 2022-2024 | Vivitrol, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $64.62 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $63.76 | 2024-2025 | Abilify Asimtufii |
| Amgen INC. | $59.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $58.87 | 2019-2025 | Uzedy |
| Insmed, INC. | $57.48 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.32 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $45.51 | 2019-2022 | |
| Allergan, INC. | $33.61 | 2019-2020 | |
| Exact Sciences Corporation | $28.22 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $27.59 | 2022-2024 | Eliquis |
| Lilly USA, LLC | $26.25 | 2019-2021 | |
| Organon LLC | $24.73 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2025 | |
| Gilead Sciences, INC. | $18.12 | 2023 | |
| Glaxosmithkline, LLC. | $16.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2022 | |
| Pfizer INC. | $13.12 | 2021 | |
| Eisai INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.